Vertex Pharmaceuticals Incorporated (VRTX) Position Lifted by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 296,881 shares of the pharmaceutical company’s stock after acquiring an additional 14,066 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Vertex Pharmaceuticals were worth $45,134,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of VRTX. Keybank National Association OH increased its holdings in shares of Vertex Pharmaceuticals by 5.3% during the 2nd quarter. Keybank National Association OH now owns 4,587 shares of the pharmaceutical company’s stock worth $591,000 after acquiring an additional 232 shares during the last quarter. Commerce Bank acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $206,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $465,000. Schroder Investment Management Group increased its holdings in shares of Vertex Pharmaceuticals by 8.0% during the 2nd quarter. Schroder Investment Management Group now owns 33,398 shares of the pharmaceutical company’s stock worth $4,250,000 after acquiring an additional 2,478 shares during the last quarter. Finally, Private Advisor Group LLC increased its holdings in shares of Vertex Pharmaceuticals by 2.4% during the 2nd quarter. Private Advisor Group LLC now owns 5,457 shares of the pharmaceutical company’s stock worth $702,000 after acquiring an additional 129 shares during the last quarter. 93.09% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms recently weighed in on VRTX. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Needham & Company LLC restated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Sunday, September 17th. Cowen restated a “buy” rating and issued a $200.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, December 11th. Finally, Bank of America upgraded Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $180.00 price target for the company in a research note on Friday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $175.81.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at $155.69 on Monday. The firm has a market capitalization of $39,370.00, a price-to-earnings ratio of 199.60, a PEG ratio of 1.97 and a beta of 1.58. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1 year low of $77.09 and a 1 year high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. The firm had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company’s revenue was up 39.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.16 EPS. sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current year.
In other news, CEO Jeffrey M. Leiden sold 125,000 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the completion of the sale, the chief executive officer now directly owns 237,407 shares in the company, valued at approximately $33,557,479.45. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 3,438 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $151.80, for a total value of $521,888.40. Following the sale, the chief marketing officer now owns 57,862 shares of the company’s stock, valued at $8,783,451.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 345,586 shares of company stock valued at $49,802,201. Corporate insiders own 1.80% of the company’s stock.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.